Chemotherapy has historically been the mainstay of cancer treatment, but our
understanding of what drives a successful therapeutic response remains limited. The …

Cancer immunogenomics is an emerging field that bridges genomics and immunology. The
establishment of large-scale genomic collaborative efforts along with the development of …

Background In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus
ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with …

Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent
approval of combination immune checkpoint blockade. Here we report the results of the …

Cancer remains a leading cause of death worldwide, placing a significant burden on
healthcare systems as well as the global economy. Rare cancers comprise a group of about …

Over the past decade, immune-checkpoint inhibitors (ICIs) have revolutionized the treatment
of cancer. In mesothelioma, a rare cancer with a dismal prognosis generally caused by …

Malignant pleural mesothelioma (MPM) is a rare malignancy with few treatment options.
Recent advances have led to US Food and Drug Administration approvals and changes in …

Background Different clinical trials for advanced esophageal cancer have investigated
diverse immuno-oncology combinational treatment in first-line setting, but the optimal choice …

Simple Summary Mesothelioma is a cancer of the lining of the lungs caused by breathing in
asbestos fibres. Asbestos was widely used in industry in the last century in most developed …

Background Malignant pleural mesothelioma (MPM) has a poor overall survival with few
treatment options. Whole genome sequencing (WGS) combined with the immune features of …